Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information


Diepenbeek, BEL
Agoralaan building A-bis
Diepenbeek, 3590, BEL




Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that are difficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.

Recent Milestones

  • Dollar
    Complix received $15.4M (€12M) in Series B funding. (6/26/13)
    Posted 6/26/13 at 1:43am via
  • Dollar
    Complix received $2.76M (€2M) in Series A funding. (2/2/11)
    Posted 2/2/11 at 8:48pm via
  • Dollar
    Complix received $6.2M in Series A funding. (6/10/10)
    Posted 6/10/10 at 5:02pm via




  1. Complix, NV: Series A $6.2M ( [edit]
  2. Complix Raises Additional €2M from Crédit Agricole Private Equity ( [edit]
  3. Complix Raises €12 Million (US$15.5 million) in Series B Round ( [edit]
Edit This Page
Last Edited 11/24/13

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy